• Recruiting

NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Updated: May 25

Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06

NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma


emb-06

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma


The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.


Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd


Locations

Australia

China

 

ClinicalTrials.gov Identifier: NCT04735575


Official Title: A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma


First Posted : February 3, 2021


Click here to see details on ClinicalTrials.gov

 

Biological: EMB-06

EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.

 

EMB-06


Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06 (Code C179632)

Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06

Anti-BCMA/Anti-CD3 FIT-Ig Bispecific Antibody EMB-06

Anti-BCMA/CD3 Bispecific Antibody EMB-06

BCMAxCD3 Bispecific Antibody EMB-06

EMB 06

EMB-06

EMB06

Fabs-In-Tandem Immunoglobulin Bispecific Antibody EMB-06

 

Locations

Australia, Queensland

Australia, Victoria

Australia, Western Australia

China, Beijing

China, Shanghai



Posts Archive